Short answer
TransMedics Group, Inc. (TMDX) filed its Q2 2026 10-Q quarterly report on Aug 4, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $190M (up 20.7% year over year) with net income of $15M.
Q2 2026 key financials · XBRL
- Revenue
- $190M
- +20.7% YoY · +9.2% QoQ
- Net income
- $15M
- −57.9% YoY · +100.7% QoQ
- Operating margin
- 12.5%
- Gross margin
- 59.6%
- EPS (diluted)
- $0.41
- −55.4% YoY · +105.0% QoQ
Source: XBRL data from the TransMedics Group, Inc. (TMDX) Q2 2026 10-Q on SEC EDGAR. USD.
TransMedics Group, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $189.9M, up $32.6M YoY from $157.4M, driven by OCS Liver and NOP usage
- Gross margin 60% vs 61% YoY; product margin 77% vs 80%, service margin 35% vs 32%
- Best segment OCS Liver revenue $148.0M vs $115.9M; worst OCS Lung revenue $2.7M vs $4.6M
- Net income $14.7M vs $34.9M; operating income $23.7M vs $36.6M
- Full-year 2026 effective tax rate guidance 25%-27%; tariffs, inflation and supply-chain volatility remain headwinds
Risk Factors
- No risk-factors section provided in submitted excerpt
- Fourth Credit Agreement amendment dated January 8, 2026, indicating changed debt-financing documentation
- No disclosed regulatory, legal, operational, competitive, market, liquidity, currency, or concentration risks in excerpt
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other TransMedics Group, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.